From The

Expert perspectives focused on the latest bioanalytical topic & trends

Update on CAR T-Cell Therapies for the Treatment of Cancer

Chimeric Antigen Receptor (CAR) therapies are a type of cell therapy that consists of modifying immune cells to attack various forms of cancerous cells. While this is a relatively new therapeutic class, there are already a number of versions that are being developed or already approved for treatment.   Let’s start with the source of the

Challenges for Measuring Immunogenicity of AAV-based Gene Therapies

Gene therapy is a powerful form of treatment that involves introducing genetic material into cells to replace defective genes resulting in the production of an essential protein. If a defective gene causes a required protein to be faulty or absent, gene therapy may be able to restore the protein’s function by introducing a “healthy” copy

Cell-Based NAb Assays: What We Need to Know

Cell-Based NAb Assays So, how do we deal with NAbs when it comes to the industrial production of biotherapeutic agents? The bioanalytical community adopts a tiered approach to tackle the problem of NAbs. Firstly, any study samples in question are first screened and confirmed for the presence of binding antibodies via an established immunoassay. If

Cell and Gene Therapies Account for a Large Portion of the Therapeutics Market

Cell and gene therapies have gone through a growth spurt in the last decade. According to data from the Alliance for Regenerative Medicine (ARM), during the first three quarters of 2020, regenerative medicine research and development broke records at nearly $16 billion in global financing. From the treatment of knee injuries to osteoarthritis, certain cancers

BioAgilytix Team Q&A: Meet Chris Carlin

  Tell us a little about your background and how you came to join BioAgilytix.   My first wet lab experience was gained during my undergrad studies at Bowdoin College in southern Maine. I majored in biology and completed an honors thesis through an exploratory study of an uncharacterized genetic locus in a pathogenic yeast.

BioAgilytix Team Q&A: Meet Reema Davis

  Tell us a little about your background and how you came to join BioAgilytix.   I did my doctoral and postdoctoral training in Cell Biology. My fascination with blood and lymphatic vessels led me to research their genetic make-up and related diseases, in hopes to find potential drug targets. During my research I trained

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.